SOUTH SAN FRANCISCO, Calif. — October 2, 2025 — Leads & Copy — Tenaya Therapeutics, Inc. (NASDAQ: TNYA) has announced that its Chief Executive Officer, Faraz Ali, will participate in investor and industry conferences in October. Ali will be at the Cell & Gene Meeting on the Mesa on October 6 for a panel discussion at 8:00 AM MT and a company presentation at 12:00 PM MT. He will also participate in the Chardan Annual Genetic Medicines Conference on October 21 for a panel discussion at 12:00 PM ET. The live webcast of the In Vivo Gene Therapies for Genetic Cardiac Diseases Panel Discussion may be accessed from the Investors section of Tenaya’s website, with an archived replay available for 30 days following the conference.
Tenaya Therapeutics is a clinical-stage biotechnology company focused on discovering, developing, and delivering curative therapies for heart disease. The company’s pipeline includes clinical-stage candidates TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), and TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Tenaya also has TN-301, a clinical-stage small molecule HDAC6 inhibitor for the potential treatment of heart failure, and multiple early-stage programs in preclinical development.
Tenaya Contacts:
Michelle Corral
VP, Corporate Communications and Investor Relations
IR@tenayathera.com
Investors:
Anne-Marie Fields
Precision AQ
annemarie.fields@precisionaq.com
Source: Tenaya Therapeutics
